Business Wire

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40% 1 - ...
PharmiWeb

Empagliflozin (Jardiance®) receives positive NICE recommendation for treatment of symptomatic chronic heart failure with preserved or mildly reduced ejection fraction

Bracknell, UK, 5 October 2023 – The National Institute for Health and Care Excellence (NICE) has today announced that empagliflozin (Jardiance ®) is recommended for use as an option for treating ...